ANVS vs. SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, ADCT, and VNDA
Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), ADC Therapeutics (ADCT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.
Silverback Therapeutics' return on equity of -29.62% beat Annovis Bio's return on equity.
In the previous week, Annovis Bio had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Annovis Bio and 0 mentions for Silverback Therapeutics. Annovis Bio's average media sentiment score of 0.50 beat Silverback Therapeutics' score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.
Annovis Bio received 1 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 95.00% of users gave Annovis Bio an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
Annovis Bio has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Annovis Bio presently has a consensus price target of $23.50, indicating a potential upside of 253.38%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Silverback Therapeutics.
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 38.3% of Annovis Bio shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Silverback Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Annovis Bio beats Silverback Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Annovis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Annovis Bio Competitors List
Related Companies and Tools
